ID   Hep 3B2.1-7
AC   CVCL_0326
SY   Hep 3B2_1-7; HEP3B217; Hep 3B2; HEP-3B2; HEP3B2; Hep-3B; HEP-3B; Hep 3B; Hep3B; HEP3B
DR   BTO; BTO:0000972
DR   CLO; CLO_0003702
DR   CLO; CLO_0003703
DR   CLO; CLO_0003710
DR   EFO; EFO_0002205
DR   MCCL; MCC:0000221
DR   CLDB; cl1627
DR   CLDB; cl1628
DR   CLDB; cl1629
DR   CLDB; cl1630
DR   AddexBio; C0015001/45
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HB-8064
DR   BCRC; 60434
DR   BCRJ; 0357
DR   BioSample; SAMN03473193
DR   BioSample; SAMN10988098
DR   CCLE; HEP3B217_LIVER
DR   CCRID; 3111C0001CCC000376
DR   CCRID; 3111C0001CCC000474
DR   CCRID; 3111C0002000000059
DR   CCRID; 3131C0001000700106
DR   CCRID; 3142C0001000000069
DR   CCTCC; GDC0070
DR   Cell_Model_Passport; SIDM00672
DR   CGH-DB; 454-3
DR   CGH-DB; 9069-4
DR   Cosmic; 873401
DR   Cosmic; 928140
DR   Cosmic; 934549
DR   Cosmic; 948066
DR   Cosmic; 979729
DR   Cosmic; 999851
DR   Cosmic; 1019316
DR   Cosmic; 1177682
DR   Cosmic; 1351510
DR   Cosmic; 1518225
DR   Cosmic; 1628385
DR   Cosmic; 2023864
DR   Cosmic; 2162536
DR   Cosmic; 2301557
DR   Cosmic; 2321030
DR   Cosmic; 2668282
DR   Cosmic; 2816904
DR   Cosmic; 2773181
DR   Cosmic-CLP; 1240147
DR   DepMap; ACH-000625
DR   DSMZ; ACC-93
DR   ECACC; 86062703
DR   GDSC; 1240147
DR   GEO; GSM207050
DR   GEO; GSM501778
DR   GEO; GSM565879
DR   GEO; GSM887078
DR   GEO; GSM888148
DR   GEO; GSM936759
DR   GEO; GSM1374531
DR   GEO; GSM1669879
DR   GEO; GSM2551564
DR   IARC_TP53; 30036
DR   IGRhCellID; Hep3B
DR   IZSLER; BS TCL 78
DR   KCB; KCB 200771YJ
DR   KCB; KCB 200942YJ
DR   KCLB; 88064
DR   LiGeA; CCLE_655
DR   LIMORE; Hep3B
DR   LINCS_LDP; LCL-1924
DR   Lonza; 473
DR   PharmacoDB; Hep3B2_17_538_2019
DR   PRIDE; PXD000533
DR   PRIDE; PXD000535
DR   PRIDE; PXD008190
DR   RCB; RCB2090
DR   TKG; TKG 0291
DR   TOKU-E; 1439
DR   Progenetix; CVCL_0326
DR   TOKU-E; 3574
DR   Wikidata; Q54882746
RX   DOI=10.1007/978-4-431-68349-0_4;
RX   DOI=10.11418/jtca1981.16.3_173;
RX   Patent=US4393133;
RX   PubMed=233137;
RX   PubMed=2439335;
RX   PubMed=3023526;
RX   PubMed=6248960;
RX   PubMed=6275024;
RX   PubMed=7972006;
RX   PubMed=8050184;
RX   PubMed=8224613;
RX   PubMed=8389256;
RX   PubMed=8835345;
RX   PubMed=9290701;
RX   PubMed=9359923;
RX   PubMed=10523694;
RX   PubMed=11050057;
RX   PubMed=12029633;
RX   PubMed=15767549;
RX   PubMed=20215515;
RX   PubMed=20454443;
RX   PubMed=20937217;
RX   PubMed=22460905;
RX   PubMed=23505090;
RX   PubMed=23887712;
RX   PubMed=24116068;
RX   PubMed=25574106;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29610054;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31063779;
RX   PubMed=31068700;
RX   PubMed=31378681;
RX   PubMed=31395879;
RX   PubMed=31978347;
RX   PubMed=32899426;
WW   https://www.quora.com/What-is-a-Hep-3B-cell-line
WW   https://lccl.zucmanlab.com/hcc/cellLines/Hep3B
WW   https://tcpaportal.org/mclp/
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-106.html
WW   http://www.brics.ac.cn/article-template.html?articleId=411&columnId=18
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: JFCR45 cancer cell line panel.
CC   Part of: Liver Cancer Model Repository (LIMORE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: African American.
CC   Doubling time: 28.05 hours (PubMed=31378681); ~40-50 hours (DSMZ).
CC   Karyotypic information: Has lost chromosome Y.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (PubMed=31395879; CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (PubMed=31395879; CCLE; Cosmic-CLP).
CC   Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=71.82%; Native American=0.52%; East Asian, North=3.16%; East Asian, South=0%; South Asian=0%; European, North=8.8%; European, South=15.69% (PubMed=30894373).
CC   Misspelling: Hep_3B1_1-7; In Cosmic 2773181.
CC   Discontinued: RCB; RCB2090; true.
ST   Source(s): AddexBio; ATCC; CCRID; Cosmic-CLP; DSMZ; ECACC; KCLB; PubMed=24116068; PubMed=25877200; PubMed=31378681
ST   Amelogenin: X
ST   CSF1PO: 8
ST   D13S317: 12,14
ST   D16S539: 10
ST   D18S51: 20
ST   D19S433: 12.2,14
ST   D21S11: 30,31
ST   D2S1338: 21,25
ST   D3S1358: 15
ST   D5S818: 13
ST   D7S820: 8,10
ST   D8S1179: 12
ST   FGA: 18
ST   Penta D: 12,14
ST   Penta E: 5,16
ST   TH01: 6,7
ST   TPOX: 9
ST   vWA: 17
DI   NCIt; C7955; Childhood hepatocellular carcinoma
DI   ORDO; Orphanet_33402; Pediatric hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   8Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 37
//
RX   DOI=10.1007/978-4-431-68349-0_4;
RA   Alexander J.J.;
RT   "Human hepatoma cell lines.";
RL   (In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987).
//
RX   DOI=10.11418/jtca1981.16.3_173;
RA   Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I.,
RA   Ohashi R., Namba M.;
RT   "The p53 gene status and other cellular characteristics of human cell
RT   lines maintained in our laboratory.";
RL   Tissue Cult. Res. Commun. 16:173-178(1997).
//
RX   Patent=US4393133;
RA   Knowles B.B., Aden D.P.;
RT   "Human hepatoma derived cell line, process for preparation thereof,
RT   and uses therefor.";
RL   Patent number US4393133, 12-Jul-1983.
//
RX   PubMed=233137; DOI=10.1038/282615a0;
RA   Aden D.P., Fogel A., Plotkin S.A., Damjanov I., Knowles B.B.;
RT   "Controlled synthesis of HBsAg in a differentiated human liver
RT   carcinoma-derived cell line.";
RL   Nature 282:615-616(1979).
//
RX   PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x;
RA   Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.J.,
RA   Revillard J.-P.;
RT   "Purification of alpha 1-microglobulin produced by human hepatoma cell
RT   lines. Biochemical characterization and comparison with alpha
RT   1-microglobulin synthesized by human hepatocytes.";
RL   Eur. J. Biochem. 165:699-704(1987).
//
RX   PubMed=3023526; DOI=10.1099/0022-1317-67-11-2315;
RA   Aspinall S., Alexander J., Bos P.;
RT   "Comparative expression of hepatitis B virus antigens in several cell
RT   model systems.";
RL   J. Gen. Virol. 67:2315-2323(1986).
//
RX   PubMed=6248960; DOI=10.1126/science.6248960;
RA   Knowles B.B., Howe C.C., Aden D.P.;
RT   "Human hepatocellular carcinoma cell lines secrete the major plasma
RT   proteins and hepatitis B surface antigen.";
RL   Science 209:497-499(1980).
//
RX   PubMed=6275024; DOI=10.1099/0022-1317-57-1-95;
RA   Koshy R., Maupas P., Muller R., Hofschneider P.H.;
RT   "Detection of hepatitis B virus-specific DNA in the genomes of human
RT   hepatocellular carcinoma and liver cirrhosis tissues.";
RL   J. Gen. Virol. 57:95-102(1981).
//
RX   PubMed=7972006; DOI=10.1073/pnas.91.23.11045;
RA   Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P.,
RA   Bennett W.P., Forrester K., Gerwin B., Serrano M., Beach D.H.,
RA   Harris C.C.;
RT   "Mutations and altered expression of p16INK4 in human cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).
//
RX   PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x;
RA   Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.;
RT   "HLA expression in hepatocellular carcinoma cell lines.";
RL   Clin. Exp. Immunol. 97:328-333(1994).
//
RX   PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613;
RA   Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E.,
RA   Ponchel F., Yakicier C., Ji J.-W., Ozturk M.;
RT   "Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell
RT   lines.";
RL   FASEB J. 7:1407-1413(1993).
//
RX   PubMed=8389256; DOI=10.1093/carcin/14.5.987;
RA   Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T.,
RA   Harris C.C.;
RT   "p53 gene mutation and integrated hepatitis B viral DNA sequences in
RT   human liver cancer cell lines.";
RL   Carcinogenesis 14:987-992(1993).
//
RX   PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2<133::AID-JMV3>3.0.CO;2-A;
RA   Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K.-I., Teruya K.,
RA   Kosaka T., Tsuji T., Namba M.;
RT   "Persistence of hepatitis C virus RNA in established human
RT   hepatocellular carcinoma cell lines.";
RL   J. Med. Virol. 48:133-140(1996).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9359923; DOI=10.18926/AMO/30789;
RA   Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y.,
RA   Fukaya K.-I., Ishioka C., Namba M.;
RT   "Yeast functional assay of the p53 gene status in human cell lines
RT   maintained in our laboratory.";
RL   Acta Med. Okayama 51:261-265(1997).
//
RX   PubMed=10523694; DOI=10.3892/or.6.6.1267;
RA   Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.;
RT   "Yeast functional assay of the p53 gene status in 11 cell lines and 26
RT   surgical specimens of human hepatocellular carcinoma.";
RL   Oncol. Rep. 6:1267-1271(1999).
//
RX   PubMed=11050057; DOI=10.1053/jhep.2000.19349;
RA   Wong N., Lai P., Pang E., Leung T.W.-T., Lau J.W.-L., Johnson P.J.;
RT   "A comprehensive karyotypic study on human hepatocellular carcinoma by
RT   spectral karyotyping.";
RL   Hepatology 32:1060-1068(2000).
//
RX   PubMed=12029633; DOI=10.1053/jhep.2002.33683;
RA   Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M.,
RA   Inazawa J.;
RT   "TFDP1, CUL4A, and CDC16 identified as targets for amplification at
RT   13q34 in hepatocellular carcinomas.";
RL   Hepatology 35:1476-1484(2002).
//
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767-904767(2010).
//
RX   PubMed=20937217; DOI=10.1170/149;
RA   Di Masi A., Viganotti M., Antoccia A., Magrelli A., Salvatore M.,
RA   Azzalin G., Tosto F., Lorenzetti S., Maranghi F., Mantovani A.,
RA   Macino G., Tanzarella C., Taruscio D.;
RT   "Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell
RT   lines by WNT/beta - catenin pathway, microRNA expression and protein
RT   expression profile.";
RL   Cell. Mol. Biol. 56:OL1299-OL1317(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23505090; DOI=10.1002/hep.26402;
RA   Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y.,
RA   Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.;
RT   "Genomic landscape of copy number aberrations enables the
RT   identification of oncogenic drivers in hepatocellular carcinoma.";
RL   Hepatology 58:706-717(2013).
//
RX   PubMed=23887712; DOI=10.1038/ncomms3218;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218-2218(2013).
//
RX   PubMed=24116068; DOI=10.1371/journal.pone.0075692;
RA   Weiskirchen R., Weimer J., Meurer S.K., Kron A., Seipel B., Vater I.,
RA   Arnold N., Siebert R., Xu L.-M., Friedman S.L., Bergmann C.;
RT   "Genetic characteristics of the human hepatic stellate cell line LX-2.";
RL   PLoS ONE 8:E75692-E75692(2013).
//
RX   PubMed=25574106; DOI=10.3748/wjg.v21.i1.311;
RA   Cevik D., Yildiz G., Ozturk M.;
RT   "Common telomerase reverse transcriptase promoter mutations in
RT   hepatocellular carcinomas from different geographical locations.";
RL   World J. Gastroenterol. 21:311-317(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29610054; DOI=10.1016/j.dmpk.2018.03.003;
RA   Shi J., Wang X., Lyu L., Jiang H., Zhu H.-J.;
RT   "Comparison of protein expression between human livers and the hepatic
RT   cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics:
RT   Focusing on drug-metabolizing enzymes.";
RL   Drug Metab. Pharmacokinet. 33:133-140(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001;
RA   Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S.,
RA   Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N.,
RA   Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P.,
RA   Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.;
RT   "Analysis of liver cancer cell lines identifies agents with likely
RT   efficacy against hepatocellular carcinoma and markers of response.";
RL   Gastroenterology 157:760-776(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001;
RA   Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J.,
RA   Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y.,
RA   Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J.,
RA   Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H.,
RA   Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X.,
RA   Hui L.-J.;
RT   "A pharmacogenomic landscape in human liver cancers.";
RL   Cancer Cell 36:179-193.e11(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574-3574(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32899426; DOI=10.3390/cancers12092510;
RA   Scherer D., Davila Lopez M., Goeppert B., Abrahamsson S.,
RA   Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D.,
RA   Umu S.U., Rounge T.B., Roessler S., Bermejo J.L.;
RT   "RNA sequencing of hepatobiliary cancer cell lines: data and
RT   applications to mutational and transcriptomic profiling.";
RL   Cancers (Basel) 12:2510.1-2510.14(2020).
//